Abstract:Genitourinary problems, including neurogenic dysfunction, impotence, prostatism, urinary tract infections, and prostate cancer, are common in the elderly, and most of the symptoms can be alleviated through pharmacological management.Patients with neurogenic dysfunction who present with symptoms such as incontinence and urinary retention can be appropriately managed with bladder and sphincter relaxants or stimulants. Anticholinergic agents in the form of oxybutynin, flavoxate, and propantheline are effective bladder relaxants, and phenoxybenzamine, prazosin, and terazosin are commonly used as sphincter relaxants. Bethanechol chloride is the agent most commonly used to stimulate bladder contraction, but physicians should be careful when prescribing it for elderly patients with cardiovascular problems.Organic and psychogenic causes of impotence usually overlap, and oral agents have limited use in the treatment process. The use of yohimbine has increased recently, but its value and rate of success remains questionable. Testosterone is being used widely to treat impotence, but it is only helpful to patients with hypogonadism and should be used with discretion in the elderly, who have a high incidence of prostate cancer. Vasoactive intracavernous pharmacotherapy, on the other hand, is a recently discovered alternative to testosterone with promising results.Although the treatment of choice for benign prostatic hypertrophy is surgery, there have been important pharmacological advances in treating this disorder. α-Adrenergic antagonists and antiandrogenic agents have been found to relieve the symptoms of prostatic enlargement.The use of chemotherapeutic and antibiotic agents to treat and suppress acute and chronic urinary tract infections is reviewed; these are second only to pulmonary infections as the most frequent cause of febrile episodes in patients over the age of 65. Lower urinary tract infections can be treated with almost any antibacterial agent. Upper urinary tract infections require full genitourinary evaluation and appropriate antibiotics should be used according to the urine culture sensitivity studies.With the advent of new hormonal agents, more choices are now available for the management of prostate cancer, which is the second most common malignancy in men. Diethylstilbestrol (stilboestrol), an oral estrogen, remains a commonly used agent to achieve castrate levels of androgens in advanced prostatic carcinoma. Agonist analogues, such as goserelin and leuprorelin, of gonadotrophin-releasing hormone (GnRH) [luteinising hormone-releasing hormone (LHRH); or gonadorelin] achieve the same results as diethylstilbestrol but without the cardiovascular side effects. Antiandrogens are also being used in combination with GnRH agonists to produce complete androgen blockage, with mixed results.

[Alpha1-Adrenoceptor Antagonists and Ejaculation Dysfunction].

Ejaculatory Dysfunction Caused by Alpha Blockers for the Treatment of Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia : A Systematic Review and Network Meta-analysis

Personalized Therapeutics of Α1-Blockers In patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Personalized Therapeutics of &Amp;alpha;1-Blockers In&nbsp;patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Characteristics of α1‐adrenoceptor antagonists‐induced ejaculatory dysfunction on spontaneous seminal emission in rats

The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews.

The Efficacy and Safety of Alpha-1 Blockers for Benign Prostatic Hyperplasia: an Overview of 15 Systematic Reviews

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review

[Progress in the Studies of Alpha1-Receptor Blocker for Benign Prostatic Hyperplasia].

Current Concepts in the Treatment of Genitourinary Tract Disorders in the Older Individual

Adrenergic alpha-1 receptor antagonists in the treatment of lower urinary tract symptoms (LUTS) in women:a systematic review

MP44-05 EARLY-ONSET SYMPTOMATIC BPH TISSUES OF MEN LESS THAN OR EQUAL TO 50 YEARS OLD APPEARED TO BE INCREASED STROMAL COMPONENTS AND VASCULARITY

Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects

Characterization of Compounds Acting on the Α1a Adrenergic Receptor Fromcaulis Spatholobiby Cell Membrane Chromatography with Possible Application for Treatment of Benign Prostatic Hyperplasia

Effects of alpha-1-adrenergic receptor subtype-selective antagonists on lower urinary tract function in rats with bladder outlet obstruction

Study on Phenylethylamines New Compounds Against Benign Prostatic Hyperplasia

Mechanism Connection between Benign Prostatic Hyperplasia and Erectile Dysfunction and the Development of New Drug Candidates

INFECTION AND INFLAMMATION OF THE GENITOURINARY TRACT the Effect of -Adrenergic Antagonists in Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Meta-Analysis of Randomized Controlled Trials

[Clinical effect of new alpha-adrenergic blocker on micturition disturbance of neurogenic bladder and lower urinary tract obstruction]

Blockade of α1A-adrenoceptor: A novel possible strategy for male contraception

Efficacy and safety of electroacupuncture for benign prostatic hyperplasia: A systematic review and meta-analysis